Log In
Print
BCIQ
Print
Print this Print this
 

solanezumab (LY2062430)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionMAb that binds to soluble beta amyloid
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD); Treat mild Alzheimer's disease (AD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today